Product.
Product.Shift has identified an initial siRNA program in liver fibrosis with first-in-class potential and the oppurtunity to expand to secondary fibrosis indications beyond the liver. In parallel Shift is assessing the potential of cell rejuvenation to impact median and maximum lifespan in aged mice.
SB101.
An antifibrotic siRNA therapeutic for cell rejuvenation.
Small molecule inhibition of SB101 could enable systemic fibrosis reversal and cell rejuvenation.
SB101 is part of a systemic fibrosis pathway and was identified as a pro-aging gene by Shift’s CLOCKWORK Target ID platform.
siRNA knockdown of SB101 ameliorates fibrosis in the liver and heart of mice (request Shift’s non-confidential deck to learn more) and reverses epigenetic aging clocks in multiple cell types in vitro. siRNA knockdown provides a straightforward regulatory path to clinical proof of concept, with first in class opportunities for an SB101 siRNA in liver fibrosis and expansion potential to secondary fibrosis (lung, heart).
SB000.
SB000.
A single gene with leading safety and efficacy profile.
Identified in 2025 (4.), Shift’s discovery of SB000 showed that cell rejuvenation could be simpler, safer and faster.
SB000 is expressed physiologically in the brain and in vitro rejuvenates multiple cell types at twice the rate of OSK with reduced oncogenic risk. Upcoming studies will assess the impact of SB000 expression on the remaining lifespan of aged mice, and explore whether SB000 can impact hearing loss in mice.
SB000 expression does not induce pluripotency with absence of iPSC colonies (white dotted lines).
